

Global Multi-Asset Viewpoint

Global Recovery Delayed, But Not Derailed

SOLUTIONS & MULTI-ASSET | GLOBAL MULTI-ASSET TEAM | MACRO INSIGHT | JANUARY 2020

In this month's letter, we address the impact of the recent outbreak of the novel coronavirus on global markets and economies, and what this means for our global investment outlook and portfolios. We believe that the likely economic impact will be a significant hit to China's growth in the first quarter of 2020, followed by a rebound in the second quarter (*Display 1*). The net impact to global GDP growth for the full year is likely to be a modest -30 basis points, based on our analysis, and assuming the virus is contained, as it appears to be.¹ This will likely extend the current "goldilocks" environment, further delaying overheating as well as the recovery in global growth that we were expecting in the first half of this year by a couple of quarters. Such an environment will likely be good for bonds, and could also be good for equities if most major equity markets look through the near-term first quarter economic impact, taking into account both the drop and the rebound in activity.

In the second half of February, reports of a rapidly-spreading coronavirus in Wuhan, Hubei Province, China caused fears of a global pandemic. Growth-sensitive assets sold off: from January 17-31, global equities fell -3.6%, U.S. 10-year Treasury yields fell by over -30 basis points to 1.51%, and Brent oil and China H-shares were each down over -10%.² Most markets have since rebounded, as it appears the virus may be contained. But the economic impact of the containment on China's economy is likely to be substantial.

AUTHORS



SERGEI PARMENOV


Portfolio Manager
Global Multi-Asset Team
Managing Director



CYRIL MOULLÉ-BERTEAUX

Portfolio Manager
Head of Global Multi-Asset Team
Managing Director

Display 1: Coronavirus Impact: 1Q 2020 Drop in GDP Growth, Followed by Q2 Rebound



Source: MSIM Global Multi-Asset team analysis, Haver analytics. Data as of February 13, 2020.


Forecasts/estimates are based on current market conditions, subject to change, and may not necessarily come to pass.

The SARS virus infected 8,421 people over the course of six months in 2002-03. Clearly, having infected over 75,000 people in just over a month, the coronavirus has sickened more people, more quickly. While China's containment measures appear to have been effective, this means China will likely bear the brunt of the economic impact. But China's economy represents a much larger share of global GDP today (18% vs. 5% in 2003), and tourism and leisure represent a larger share of the global economy.³

We estimate that China growth could decelerate from 6% in the fourth quarter of 2019 to -1% in the first quarter of 2020, quarter-over-quarter, seasonally-adjusted annual rate (QoQ SAAR). This is based on our assessment of the impact of measures to contain the virus (e.g. travel restrictions, extension of the Lunar New Year). We estimate that the impact to global growth will be a deceleration from the 2.6% pre-outbreak run-rate to 0.7% in the first quarter (QoQ SAAR), with the global PMI falling from the current 51.9 to 45.0 at the trough.⁴

We then expect a big make-up bounce in the second quarter in China (+9%) and global (+3.4%) growth (QoQ SAAR), once China lifts travel restrictions and economic activity returns to normal. By the second half of 2020, we believe China and the global economy could return to roughly their fourth quarter 2019 pace of growth. The permanent loss as a result of demand destruction in the first quarter would be -100 basis points lower growth for China for the full year and -30 basis points lower for global growth, based on these estimates. We are now expecting 2.2% global growth for the full year 2020 on a year-over-year basis, compared with 2.5% previously (*Display 2*).⁵

Display 2: Permanent Loss in GDP Growth from Coronavirus Modest



Source: MSIM Global Multi-Asset team estimates.
Data as of February 13, 2020.


Forecasts/estimates are based on current market conditions, subject to change, and may not necessarily come to pass.

We expect that the market will look through the first quarter impact on growth, taking into account both the drop and the rebound in activity in essence, looking at the first half in its entirety. If so, the U.S. 10-year Treasury yield could fall as low as 1.25% in the first half of the year—discounting the drop in global growth for the combined first half of the year to 2.1%, rather than the actual first quarter trough of 0.8% that we believe is likely. By the second half of the year, if growth recovers to its pre-coronavirus baseline, the 10-year Treasury yield could rise back to pre-virus levels of roughly 1.85%. In equity markets, we expect modest mid-single digit additional downside in China and emerging market equities from current levels, while most of the damage to U.S. equities has likely already played out. We forecast moderate additional upside for gold through the end of the year; our year end-2020 target for gold is \$1900 per ounce.⁶

We are watching the number of new cases for evidence of containment, given that in historically similar episodes, such as SARS, markets have looked to a peak in the number of new daily cases as an indication that the virus is under control. In 2003, the bottom in Hong Kong equity market performance relative to global equities coincided roughly with the April 2003 peak in the number of new SARS cases.⁷ The daily incremental number of new coronavirus cases appears to be peaking now, both within and outside of China, with the peak in the number of daily incremental new cases potentially reached in the first half of February. The percentage change in daily new cases has been falling, such that the number of daily incremental new cases has declined (with the exception of what we expect to be a temporary pop in new cases in Hubei as a result of a new testing methodology) (*Display 3*). In addition, the virus appears to have been mostly limited within Hubei province, China (Hubei accounts for 4% of Chinese GDP), where about 80% of all confirmed cases are located. Greater China outside of Hubei accounts for another 20% of total cases, while global cases outside of China represent just 1% of the total number of cases.⁸

Our economic and market forecasts assume that the virus is contained relatively quickly, by the end of February. However, one of the risks to our view is that the epidemic turns out to be much worse than currently understood. Under-reporting or delayed reporting in Hubei province, given resource constraints there, or a more aggressive spreading of the virus within and beyond China as individuals return to work could cause a longer period of travel restrictions or a slower re-starting of China-based production from Chinese and international companies. Another possibility is that the slowdown is exacerbated by excess leverage in China's economy. Any of these could cause the economic impact to be bigger, with the subsequent recovery being slower, and could cause us to revise down our economic and market projections.

Display 3: Virus Contained - Daily Incremental Change in New Cases Coming Down



Source: MSIM Global Multi-Asset team analysis, China's National Health Commission, World Health Organization, John Hopkins University. Data as of February 18, 2020.

On the other hand, an upside risk to our view is that more aggressive monetary policy easing in China and potentially by the Fed could generate a bigger growth rebound. Indeed, recent statements from the People's Bank of China appear to indicate a prioritization of economic support over debt reduction amid the crisis.

Recognizing near-term risks to growth and earnings, we have taken equity and bond exposure to neutral from overweight equities and underweight bonds. We reduced positions in value stocks relative to low volatility and momentum stocks in the U.S. and Europe, where valuation and sentiment are extreme, but we are awaiting evidence of the key fundamental driver of this trade which is evidence that global growth is imminently rebounding, before adding back to these positions.

RISK CONSIDERATIONS

There is no assurance that a portfolio will achieve its investment objective. Portfolios are subject to market risk, which is the possibility that the market values of securities owned by the portfolio will decline and that the value of portfolio shares may therefore be less than what you paid for them. Accordingly, you can lose money investing in this portfolio. Please be aware that this portfolio may be subject to certain additional risks. In general, **equity securities**' values fluctuate in response to activities specific to a company. Investments in foreign markets entail special risks such as currency, political, economic, and market risks. The risks of investing in **emerging market countries** are greater than risks associated with investments in foreign developed countries. **Fixed-income securities** are subject to the ability of an issuer to make timely principal and interest payments (credit risk), changes in interest rates (interest-rate risk), the creditworthiness of the issuer and general market liquidity (market risk). In a rising interest-rate environment, bond prices may fall and may result in periods of volatility and increased portfolio redemptions. In a declining interest-rate environment, the portfolio may generate less income. **Longer-term securities** may be more sensitive to interest rate changes. **Mortgage- and asset-backed securities (MBS and ABS)** are sensitive to early prepayment risk and a higher risk of default and may be hard to value and difficult to sell (liquidity risk). They are also subject to credit, market and interest rate risks. Certain **U.S. government securities** purchased by the Portfolio, such as those issued by Fannie Mae and Freddie Mac, are not backed by the full faith and credit of the United States. It is possible that these issuers will not have the funds to meet their payment obligations in the future. The issuer or governmental authority that controls the repayment of **sovereign debt** may not be willing or able to repay the principal and/ or pay interest when due in accordance with the terms of such obligations. Investments in **foreign markets** entail special risks such as currency, political, economic, and market risks. The risks of investing in **emerging market countries** are greater than risks associated with investments in foreign developed countries.

Real estate investment trusts are subject to risks similar to those associated with the direct ownership of real estate and they are sensitive to such factors as management skills and changes in tax laws. **Restricted and illiquid securities** may be more difficult to sell and value than publicly traded securities (liquidity risk). **Derivative instruments** can be illiquid, may disproportionately increase losses and may have a potentially large negative impact on the Portfolio's performance. Trading in, and investment exposure to, the **commodities** markets may involve substantial risks and subject the Portfolio to greater volatility. **Nondiversified portfolios** often invest in a more limited number of issuers. As such, changes in the financial condition or market value of a single issuer may cause greater volatility. By investing in **investment company securities**, the portfolio is subject to the underlying risks of that investment company's portfolio securities. In addition to the Portfolio's fees and expenses, the Portfolio generally would bear its share of the investment company's fees and expenses. **Subsidiary and Tax Risk** The Portfolio may seek to gain exposure to the commodity markets through investments in the Subsidiary or commodity index-linked structured notes. The Subsidiary is not registered under the 1940 Act and is not subject to all the investor protections of the 1940 Act. Historically, the Internal Revenue Service ("IRS") has issued private letter rulings in which the IRS specifically concluded that income and gains from investments in commodity index-linked structured notes or a wholly-owned foreign subsidiary that invests in commodity-linked instruments are "qualifying income" for purposes of compliance with Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code"). The Portfolio has not received such a private letter ruling, and is not able to rely on private letter rulings issued to other taxpayers. If the Portfolio failed to qualify as a regulated investment company, it would be subject to federal and state income tax on all of its taxable income at regular corporate tax rates with no deduction for any distributions paid to shareholders, which would significantly adversely affect the returns to, and could cause substantial losses for, Portfolio shareholders.

FOOTNOTES

¹ MSIM Global Multi-Asset Team analysis and estimates

² MSIM Global Multi-Asset Team analysis; Bloomberg

³ MSIM Global Multi-Asset Team analysis; Haver Analytics

⁴ MSIM Global Multi-Asset Team analysis and estimates

⁵ MSIM Global Multi-Asset Team analysis and estimates

⁶ MSIM Global Multi-Asset Team analysis and estimates

⁷ MSIM Global Multi-Asset Team analysis; Bloomberg

⁸ MSIM Global Multi-Asset Team analysis; Haver Analytics; China's National Health Commission; World Health Organization; John Hopkins University

DEFINITIONS

The Russell 1000® Growth Index measures the performance of the large-cap growth segment of the U.S. equity universe. It includes those Russell 1000® Index companies with higher price-to-book ratios and higher forecasted growth values. The Russell 1000® Index is an index of approximately 1,000 of the largest U.S. companies based on a combination of market capitalization and current index membership.

The Russell 1000® Value Index is an index that measures the performance of those Russell 1000 companies with lower price-to-book ratios and lower forecasted growth values.

The S&P 500 Total Return Index is an index that consists of 500 stocks chosen for market size, liquidity and industry group representation. The S&P Index is a market value weighted index with each stock's weight proportionate to its market value. The S&P Index is one of the most widely used benchmarks of U.S. equity performance. The performance of the S&P Index does not account for any management fees, incentive compensation, commissions or other expenses that would be incurred pursuing such strategy. Total return provides investors with a price-plus-gross cash dividend return. Gross cash dividends are applied on the ex-date of the dividend.

IMPORTANT DISCLOSURES

The views and opinions are those of the author as of the date of publication and are subject to change at any time due to market or economic conditions and may not necessarily come to pass. Furthermore, the views will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date of publication. The views expressed do not reflect the opinions of all portfolio managers at Morgan Stanley Investment Management (MSIM) or the views of the firm as a whole, and may not be reflected in all the strategies and products that the Firm offers.

Forecasts and/or estimates provided herein are subject to change and may not actually come to pass. Information regarding expected market returns and market outlooks is based on the research, analysis and opinions of the authors. These conclusions are speculative in nature, may not come to pass and are not intended to predict the future performance of any specific Morgan Stanley Investment Management product.

Certain information herein is based on data obtained from third party sources believed to be reliable. However, we have not verified this information, and we make no representations whatsoever as to its accuracy or completeness.

This material is a general communication, which is not impartial and all information provided has been prepared solely for information purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

Charts and graphs provided herein are for illustrative purposes only.

Past performance is no guarantee of future results.

This communication is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

The indexes are unmanaged and do not include any expenses, fees or sales charges. It is not possible to invest directly in an index. Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto.

There is no guarantee that any investment strategy will work under all market conditions, and each investor should evaluate their ability to invest for the long-term, especially during periods of downturn in the market. Prior to investing, investors should carefully review the strategy's / product's relevant offering document. There are important differences in how the strategy is carried out in each of the investment vehicles.

DISTRIBUTION

This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations.

United Kingdom: Morgan Stanley Investment Management Limited is authorised and regulated by the Financial Conduct Authority. Registered in England. Registered No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA, authorised and regulated by the Financial Conduct Authority.

Dubai: Morgan Stanley Investment Management Limited (Representative Office, Unit Precinct 3-7th Floor-Unit 701 and 702, Level 7, Gate Precinct Building 3, Dubai International Financial Centre, Dubai, 506501, United Arab Emirates. Telephone: +97 (0)14 709 7158). **Germany:** Morgan Stanley Investment Management Limited Niederlassung Deutschland, Grosse Gallusstrasse 18, 60312 Frankfurt am Main, Germany (Gattung: Zweigniederlassung (FDI) gem. § 53b KWG). **Ireland:** Morgan Stanley Investment Management (Ireland) Limited. Registered Office: The Observatory, 7-11 Sir John Rogerson's, Quay, Dublin 2, Ireland. Registered in Ireland under company number 616662. Authorised and regulated by Central Bank of Ireland. **Italy:** Morgan Stanley Investment Management Limited, Milan Branch (Sede Secondaria di Milano) is a branch of Morgan Stanley Investment Management Limited, a company registered in the UK, authorised and regulated by the Financial Conduct Authority (FCA), and whose registered office is at 25 Cabot Square, Canary Wharf, London, E14 4QA. Morgan Stanley Investment Management Limited Milan Branch (Sede Secondaria di Milano) with seat in Palazzo Serbelloni Corso Venezia, 16 20121 Milano, Italy, is registered in Italy with company number and VAT number 08829360968.

The Netherlands: Morgan Stanley Investment Management, Rembrandt Tower, 11th Floor Amstelplein 1 1096HA, Netherlands. Telephone: 31 2-0462-1300. Morgan Stanley Investment Management is a branch office of Morgan Stanley Investment Management Limited. Morgan Stanley Investment Management Limited is authorised and regulated by the Financial Conduct Authority in the United Kingdom. **Switzerland:** Morgan Stanley & Co. International plc, London, Zurich Branch Authorised and regulated by the Eidgenössische Finanzmarktaufsicht ("FINMA"). Registered with the Register of Commerce Zurich CHE-115.415.770. Registered Office: Beethovenstrasse 33, 8002 Zurich, Switzerland, Telephone +41 (0) 44 588 1000. Facsimile Fax: +41(0) 44 588 1074.

Hong Kong: This document has been issued by Morgan Stanley Asia Limited for use in Hong Kong and shall only be made available to "professional investors" as defined under the Securities and Futures Ordinance of Hong Kong (Cap 571). The contents of this document have not been reviewed nor approved by any regulatory authority including the Securities and Futures Commission in Hong Kong. Accordingly, save where an exemption is available under the relevant law, this document shall not be issued, circulated, distributed, directed at, or made available to, the public in Hong Kong. **Singapore:** This document should not be considered to be the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor under section 304 of the Securities and Futures Act, Chapter 289 of Singapore ("SFA"); (ii) to a "relevant person" (which includes an accredited investor) pursuant to section 305 of the SFA, and such distribution is in accordance with the conditions specified in section 305 of the SFA; or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This publication has not been reviewed by the Monetary Authority of Singapore. **Australia:** This publication is disseminated in Australia by Morgan Stanley Investment Management (Australia) Pty Limited ACN: 122040037, AFSL No. 314182, which accept responsibility for its contents. This publication, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. **Japan:** For professional investors, this document is circulated or distributed for informational purposes only. For those who are not professional investors, this document is provided in relation to Morgan Stanley Investment Management (Japan) Co., Ltd. ("MSIMJ")'s business with respect to discretionary investment management agreements ("IMA") and investment advisory agreements ("IAA"). This is not for the purpose of a recommendation or solicitation of transactions or offers any particular financial instruments. Under an IMA, with respect to management of assets of a client, the client prescribes basic management policies in advance and commissions MSIMJ to make all investment decisions based on an analysis of the value, etc. of the securities, and MSIMJ accepts such commission. The client shall delegate to MSIMJ the authorities necessary for making investment. MSIMJ exercises the delegated authorities based on investment decisions of MSIMJ, and the client shall not make individual instructions. All investment profits and losses belong to the clients; principal is not guaranteed. Please consider the investment objectives and nature of risks before investing. As an investment advisory fee for an IAA or an IMA, the amount of assets subject to the contract multiplied by a certain rate (the upper limit is 2.20% per annum (including tax)) shall be incurred in proportion to the contract period. For some strategies, a contingency fee may be incurred in addition to the fee mentioned above. Indirect charges also may be incurred, such as brokerage commissions for incorporated securities. Since these charges and expenses are different depending on a contract and other factors, MSIMJ cannot present the rates, upper limits, etc. in advance. All clients should read the Documents Provided Prior to the Conclusion of a Contract carefully before executing an agreement. This document is disseminated in Japan by MSIMJ, Registered No. 410 (Director of Kanto Local Finance Bureau (Financial Instruments Firms)), Membership: the Japan Securities Dealers Association, The Investment Trusts Association, Japan, the Japan Investment Advisers Association and the Type II Financial Instruments Firms Association.

U.S.:

A separately managed account may not be suitable for all investors. Separate accounts managed according to the Strategy include a number of securities and will not necessarily track the performance of any index. Please consider the investment objectives, risks and fees of the Strategy carefully before investing. A minimum asset level is required. For important information about the investment manager, please refer to Form ADV Part 2.

Please consider the investment objectives, risks, charges and expenses of the funds carefully before investing. The prospectuses contain this and other information about the funds. To obtain a prospectus please download one at morganstanley.com/im or call 1-800-548-7786. Please read the prospectus carefully before investing.

Morgan Stanley Distribution, Inc. serves as the distributor for Morgan Stanley funds.

NOT FDIC INSURED | OFFER NO BANK GUARANTEE | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A DEPOSIT

IMPORTANT INFORMATION

EMEA: This marketing communication has been issued by Morgan Stanley Investment Management Ireland Limited ("MSIM Ireland"). Authorised and regulated by the Financial Conduct Authority. Registered in England No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA.

The information contained in this communication is not a research recommendation or 'investment research' and is classified as a 'Marketing Communication' in accordance with the applicable European or Swiss regulation. This means that this marketing communication (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research.

MSIM has not authorised financial intermediaries to use and to distribute this document, unless such use and distribution is made in accordance with applicable law and regulation. Additionally, financial intermediaries are required to satisfy themselves that the information in this document is suitable for any person to whom they provide this document in view of that person's circumstances and purpose. MSIM shall not be liable for, and accepts no liability for, the use or misuse of this document by any such financial intermediary.

This document may be translated into other languages. Where such a translation is made this English version remains definitive. If there are any discrepancies between the English version and any version of this document in another language, the English version shall prevail.

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without MSIM's express written consent.